Humana Inc. has finalized an agreement to sell its 40% minority stake in Gentiva, a national provider of hospice, palliative, and personal care services, for approximately $900 million. The transaction, announced by the Louisville-based health insurer, marks the final stage of Humana’s strategic exit from the direct ownership of these clinical service lines, with the divestiture expected to conclude in the third quarter of 2026, subject to customary regulatory approvals and closing conditions.
This divestiture represents the culmination of a multi-year restructuring process for Humana’s home-based care portfolio. According to the company’s official public disclosure, the proceeds from the sale will be allocated toward general corporate purposes. Humana, which trades on the New York Stock Exchange under the ticker symbol HUM, stated that it does not anticipate a material impact to its 2026 earnings as a result of the transaction.
The Evolution of the Humana and Gentiva Partnership
The relationship between Humana and Gentiva is rooted in the 2021 acquisition of Kindred at Home. In 2022, Humana completed the divestiture of the hospice and personal care divisions of Kindred at Home to the private equity firm Clayton, Dubilier & Rice (CD&R). While CD&R assumed majority control of the newly branded Gentiva, Humana retained a 40% non-controlling interest in the entity. This structure was designed to ensure a “full continuum of care” for Humana’s Medicare Advantage members, allowing the insurer to maintain a clinical connection to these services while offloading the operational complexities of direct provider management.
Gentiva currently operates in a significant portion of the United States, providing end-of-life and personal health services at more than 430 locations across 35 states. As Humana shifts its strategy, it is moving away from the role of a direct service provider to focus more exclusively on its core business as a managed care organization and health insurer. This transition aligns with broader industry trends where large insurance entities are increasingly separating their insurance operations from their healthcare delivery assets to simplify their business models and improve capital efficiency.
Transaction Advisors and Legal Framework
To navigate the complexities of this divestiture, Humana has engaged a suite of financial and legal experts. Guggenheim Securities, LLC is serving as the lead financial advisor for the transaction. On the legal front, the company has retained two prominent firms: Fried, Frank, Harris, Shriver & Jacobson LLP and Manatt, Phelps & Phillips LLP.
The deal involves a consortium of investors, though the specific identities of the purchasing parties have not been disclosed beyond their status as a consortium. The completion of the sale by the third quarter of 2026 remains contingent upon standard regulatory reviews, which typically include oversight regarding market competition and healthcare service continuity. For investors and stakeholders, the company’s recent filings with the U.S. Securities and Exchange Commission (SEC) provide the necessary context regarding how this $900 million influx will be reflected in the company’s broader balance sheet and capital allocation strategy.
Strategic Implications for the Home Health Sector
The divestiture of the Gentiva stake is significant for the broader home health care market. By exiting its minority position, Humana is effectively ending its direct equity ties to the hospice and personal care services it once sought to integrate fully into its clinical ecosystem. For patients and healthcare providers, the primary question remains how this change in ownership structure will affect the continuity of care for those currently receiving hospice or palliative services under Humana-affiliated plans.
Industry analysts often look to such moves as indicators of the long-term profitability and regulatory risk associated with hospice and home-based care. The hospice sector, in particular, has faced increased scrutiny regarding patient eligibility and billing practices, which may influence how large insurers view the long-term value of owning such assets. Humana’s decision to fully divest suggests a preference for a model where they purchase these services from independent providers rather than managing the clinical operations themselves.
What Happens Next?
The transaction is currently in a transition period that is expected to span several quarters. The next confirmed checkpoint for stakeholders will be the formal regulatory filing updates and any subsequent announcements regarding the satisfaction of closing conditions as the 2026 target date approaches. Humana has indicated that it will continue to provide updates to shareholders through its standard quarterly earnings calls and periodic SEC disclosures.
As the healthcare landscape continues to evolve, the separation of insurance and care delivery remains a subject of intense focus for policy makers and investors alike. Readers interested in the long-term health of the home care sector may wish to monitor future filings from both Humana and the private equity groups managing the Gentiva entity for further clarity on the integration of these services.
Have thoughts on the shifting landscape of home-based care? Please share your perspective in the comments section below.